This research aims to investigate the influence of alkyl polyglucoside (APG) as a co-surfactant in nanoemulsion formulation containing ibuprofen, as a model drug, which intended to be used for topical application. Phase behavior of oil/surfactant/water system containing ibuprofen with different surfactants Cremophor EL(CrEL)/APG ratios (9:1, 8:2, and 6:4) was investigated. The results showed the system with CrEL: APG ratio 9:1 gives the largest isotropic region. When compared to the nanoemulsion formulation with and without APG, it showed that the system with APG exhibited higher emulsifying ability than CrEL surfactant alone which due to the APG co-surfactant could decrease the water affinity and increase the oil affinity of the systems. Several formulations with different surfactant-to-oil (S:O) ratios (1:9 and 9:1) were prepared. The result showed that the formulation containing the S:O ratio of 9:1 exhibited smaller and monodisperse particle sizes than the formulation containing the S:O ratio of 1:9 and it was selected for the preparation of nanoemulsion formulations. The particle size ranged between 20 and 200 nm and a polydispersity index less than 0.25 was obtained. Cytotoxicity results showed that no cytotoxicity effect (IC₅₀ > 500 μg/mL) against 3T3 cell lines for both formulations (with and without APG) with reduced drug release when APG-corporate in nanoemulsion formulation. This shows that APG could be used as alternative stabilizing agent and the formulated nanoemulsion system could be used as a new topical drug carrier system for pharmaceutical applications.

本研究旨在研究烷基多糖苷 (APG) 作为辅助表面活性剂在含有布洛芬作为模型药物的纳米乳剂制剂中的影响，该制剂旨在用于局部应用。研究了含有布洛芬和不同表面活性剂 Cremophor EL(CrEL)/APG 比率（9:1、8:2 和 6:4）的油/表面活性剂/水系统的相行为。结果表明，CrEL:APG 比率为 9:1 的系统给出了最大的各向同性区域。与含和不含 APG 的纳米乳液配方相比，表明含 APG 的体系比单独的 CrEL 表面活性剂表现出更高的乳化能力，这是由于 APG 辅助表面活性剂可以降低体系的水亲和力并增加体系的亲油性。制备了几种具有不同表面活性剂与油 (S:O) 比（1:9 和 9:1）的配方。结果表明，S:O 比为 9:1 的配方比 S:O 比为 1:9 的配方表现出更小的单分散粒径，并被选择用于制备纳米乳剂。粒径范围在 20 到 200 nm 之间，获得的多分散指数小于 0.25。细胞毒性结果显示无细胞毒性作用（IC₅₀  > 500 μg/mL）对于两种制剂（有和没有 APG）的 3T3 细胞系，当 APG 结合在纳米乳剂制剂中时，药物释放减少。这表明 APG 可用作替代稳定剂，配制的纳米乳剂系统可用作药物应用的新型局部药物载体系统。